Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Preliminary Fiscal Q1 Revenues Drop 9 Percent

NEW YORK ─ Hologic on Sunday announced preliminary financial results for its fiscal first quarter ended Dec. 25, saying it expects total revenues of approximately $1.47 billion, a drop of 9 percent compared to $1.61 billion in Q1 2021. Analysts on average expect Q1 revenues of $1.13 billion.

On Nov. 1, 2021, Marlborough, Massachusetts-based Hologic had guided for Q1 revenues of between $1.10 billion and $1.15 billion.

"We expect to report a very strong start to fiscal 2022 across-the-board, with first quarter revenue well above our guidance," Steve MacMillan, the company’s chairman, president, and CEO, said in a statement.

In the Diagnostics division, Hologic "over-delivered in our base business while meeting heavy demand for COVID-19 testing," he said.

The firm expects fiscal Q1 Diagnostics revenues of $950.4 million, down 16 percent compared to $1.13 billion in the prior-year quarter. Excluding COVID-19 revenues, it anticipates Q1 organic Diagnostics revenues of $320.8 million, up 10 percent from $291.9 million in Q1 2021.

First quarter Breast Health revenues are expected to be $359.4 million, up 8 percent year over year compared to $332.7 million; Gynecologic Surgical revenues are expected to be $134.3 million, up 8 percent year over year compared to $124.0 million; and Skeletal Health revenues are expected to be $27.1 million, up 9 percent year over year compared to $24.9 million.

Excluding its divested blood screening business and the acquisitions of Biotheranostics, Diagenode, Mobidiag, and Bolder Surgical, Hologic expects organic Q1 revenues of $1.43 billion, down 11 percent year over year from $1.60 billion. Excluding COVID-19 revenues, it expects Q1 organic revenues of $840.9 million, up 9 percent from $773.4 million in fiscal Q1 last year. MacMillan noted that by comparison, Hologic has a long-term organic growth target of 5 to 7 percent.

The firm expects non-GAAP diluted earnings per share to be "significantly higher" than its guidance for EPS of $1.15 to $1.25 announced on Nov. 1.

Hologic expects to announce full financial results for its fiscal first quarter on Feb. 2.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.